Legend Biotech Corporation
LEGN
株式のランク
#4424
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
株価
$19.04
時価総額
$3.52B
変化（1日）
2.09%
変化（1年）
-42.15%
国
US
取引 Legend Biotech Corporation (LEGN)
カテゴリー
Healthcare
Legend Biotech Corporation（LEGN）の利益
Jun 2026 時点の利益 TTM: $-56.27M
Legend Biotech Corporation の最新の財務報告によると、同社の現在の利益は $-56.27M です。2023 年には $-520.12M の利益を上げ、これは 2022 年の利益 $-445.72M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Legend Biotech Corporation の利益の推移（2017 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-56.27M | -64.41% |
| 2024 | $-158.13M | -69.60% |
| 2023 | $-520.12M | 16.69% |
| 2022 | $-445.72M | 9.46% |
| 2021 | $-407.20M | 32.08% |
| 2020 | $-308.29M | 142.14% |
| 2019 | $-127.32M | 7,778.65% |
| 2018 | $-1.62M | -111.68% |
| 2017 | $13.84M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -9,473.93% |
US
|
|
| $-3.09B | 5,385.85% |
US
|
|
| $-4.02B | 7,037.11% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,566.47% |
NL
|
